CD8A and autosomal dominant polycystic kidney disease: However, the efficacy or side effects of such protocols were not tested in our studies and are part of future work alongside investigations focused on alternative pathways that induce immunosuppression and CD8+ T cell exhaustion, which may be targetable alone or in combination with ICIs or other epithelium-centric drugs such as tolvaptan (JYNARQUE), currently the only FDA-approved therapy for ADPKD.